# COURSE PROGRAMME





|             | MONDAY 5 M  | A1 2025  |  |
|-------------|---|--|--|
| TBC         | Bus from hotels to Les Pensières  |  |  |
| 9:00-9:30   | Opening and Objectives of the course  | Kamel Senouci, Director ADVAC,<br>University of Geneva               | Charles  |
| 9:30-9:40   | Welcome and Logistic briefing   | <b>Sandra Angèle</b> , Director, Les Pensières,<br>Fondation Mérieux | Mérieux<br>conf. room  |
|             | SESSION 1: THE VACCINE JO<br>FROM VACCINES TO VACCINATION & THE   |  | <u>Chair:</u><br><b>Adam Finn,</b><br>University of<br>Bristol |
| 9:40-10:05  | 1. From Research to individual protection:  | Arnaud Didierlaurent and Kamel                                       | 01 1   |
|             | The A-to-Z vaccine's journey  | Senouci, University of Geneva,<br>Switzerland                        | Charles<br>Mérieux<br>conf. room                               |
| 10:05-10:25 | Discussion  |  |  |
| 10:25-10:55 | Break   |  | Restaurant   |
| 10:55-11:20 | <ol><li>Vaccines Preventable Diseases' Burden and<br/>Vaccines Impact on Public Health</li></ol>                                      | Kamel Senouci, University of Geneva,                                 | Charles  |
| 11:20-11:40 | Discussion  |  | Mérieux<br>conf. room  |
| 11:40-12:05 | 3. Measuring vaccination's impact in populations  | Daniel Feikin, WHO, Geneva   |  |
| 12:05-12:25 | Discussion  |  | _  |
| 12:25-13:25 | Lunch (seated, please check the tables attributed to the speakers)  |  | Restaurant +<br>Ogobara<br>Doumbo<br>room                      |
| 13:25-13:50 | 4. Where are we with vaccine-preventable diseases<br>& immunization coverage worldwide: the state of<br>the immunization              | Kate O'Brien, WHO, Geneva  |  |
| 13:50-14:10 | Discussion  |  | -<br>Charles   |
| 14:10-14:35 | <ol> <li>Using vaccines to address a public health<br/>problem: the example of Polio eradication<br/>immunization strategy</li> </ol> | <b>Ananda Bandyopadhyay</b> , Gates Foundation, USA                  | Mérieux<br>conf. room  |
| 14:35-14:55 | Discussion  |  | -  |
| 14:55-15:10 | Time for students to reflect personally on the learnings  |  |  |
| 15:10-15:30 | Break   |  | Restaurant   |
| 15:30-16:30 | Mentoring   |  | TBC  |
| 16:30-18:00 | Self-presentation of participants (background, interests in life)   | Social Event   | Nicole<br>Mérieux rooi   |
| 18:00-20:00 | Welcome Reception   |  | Nicole<br>Mérieux root   |
| 20:00       | Bus to Hotels   |  | + Terrasse   |

## TUESDAY 6 MAY 2025

| TBC                       | Bus from hotels to Les Pensières   |  |  |
|---------------------------|--|--|--|
|                           | SESSION 2: HOW VACCINES  | WORK?  | <u>Chair:</u><br><b>Arnaud</b><br><b>Didierlauren</b><br>UNIGE |
| 09:00-09:25               | 6. How do vaccines protect?<br>Immune effectors induced by vaccines: Antibodies,<br>B and T cells, mucosal immunity          | <b>Christiane Eberhardt,</b> University of Geneva, Switzerland   |  |
| 09:25-09:45               | Discussion   |  | _<br>Charles   |
| 09:45-10:10               | 7. How are vaccines' responses elicited? What a vaccinologist should know about the basic aspects of immunological responses | <b>Arnaud Marchant</b> , Université Libre de<br>Bruxelles, Belgium   | — Mérieux<br>conf. room  |
| 10:10-10:30               | Discussion   |  | _  |
| 10:30-11:00               | Break  |  | Restaurant   |
| 11:00-11:25               | 8.How to use vaccines' platforms to tailor immune responses?   | <b>Arnaud Didierlaurent,</b> University of Geneva, Switzerland   |  |
| 11:25-11:45               | Discussion   |  | —<br>Charles   |
| 11:45-12:10               | 9.Use and limitations of correlates of immunity in vaccinology   | Adam Finn, University of Bristol, UK   | Mérieux<br>conf. room  |
| 12:10-12:30               | Discussion   |  | _  |
| 12:30-14:00               | Lunch  |  | Restaurant<br>O. Doumbo<br>room                                |
| 14:00-15:30               | Interactive Session 1:  Variability of vaccine responses in the real world   | Christiane Eberhardt, University of<br>Geneva, Switzerland & Arnaud<br>Marchant, Université Libre de Bruxelles,<br>Belgium | Charles<br>Mérieux<br>+  |
|                           | Interactive session (in 2 groups + Q&A)  | Joigian  | Simone<br>Mérieux  |
| 15:30-15:55               | 10. Immunological memory   | Rafi Ahmed, Emory University, USA  |  |
| 15:55-16:15               | Discussion   |  | Charles<br>Mérieux   |
| 16:15-16:30               | Time for students to reflect personally on the learnings   |  |  |
| 16:35-16:50               | Break  |  | Restaurant   |
| 16:50- <mark>18:30</mark> | Soccer, Mölkky, Pétanque   | Social Event   | Outside  |
| <mark>18:30</mark> -20:00 | Aperitive and Dinner   |  | Restaurant<br>Ogobara<br>Doumbo                                |
| 20:00                     | Bus to Hotels  |  |  |

### WEDNESDAY 7 MAY 2025

**TBC** Bus from hotels to Les Pensières

| SE           | SSION 3 – VACCINE TECHNOLOGY & MANUI   | FACTURING (PART ½)  | Chair: Emily<br>Erbelding,<br>Director, DMID,<br>NIH, USA       |
|--------------|--|---|---|
| 09:00-09:25  | 11. Landscape in vaccine and immunization technologies                             | Cristina Cassetti, NIH-NIAID, USA   |   |
| 09:25-09:45  | Discussion   |   | Charles Mérieux   |
| 09:45 -10:10 | 12. Vaccine market, market shaping and regional initiatives for vaccine production | Tania Cernuschi, WHO, Switzerland   | conf. Room  |
| 10:10-10:30  | Discussion   |   |   |
| 10:30-11:00  | Break  |   | Restaurant  |
| 11:00-11:25  | 13. Concepts of Chemistry, Manufacturing, and Controls (CMC) for vaccines          | Ozzie Berger, Hillevax, USA   |   |
| 11:25-11:45  | Discussion   |   |   |
| 11:45-12:10  | 14. The complexity of quality control in vaccine manufacturing                     | <b>Philippe Juvin</b> , Sanofi Pasteur,<br>France   | Charles Mérieux   |
| 12:10-12:30  | Discussion   |   |   |
| 12:30-12:45  | Time for students to reflect personally on the learnings                           |   |   |
| 12:45-14:00  | Lunch  |   | Restaurant +<br>Ogobara<br>Doumbo                               |
|              | SESSION 4 – VACCINE REGULA   | TORY  | <u>Chair:</u> Emily<br>Erbelding,<br>Director, DMID<br>NIH, USA |
| 14:00-14:25  | 15. The role of Regulatory Agencies  | Marco Cavaleri, EMA, The<br>Netherlands   | Charles Mérieu  |
| 14:25-14:45  | Discussion   |   |   |
| 14:45-16:30  | Small Group Exercise 1:  | Norman Baylor, Biologics Consulting<br>Group, USA, Ozzie Berger, Hillevax   | Charles Mérieu  |
|              | Vaccine Regulatory   | USA, <b>Donna Boyce</b> , Pfizer USA,<br><b>Marco Cavaleri</b> , EMA, Netherland,   | + Ogobara<br>Doumbo   |
|              | 4 Groups   | Arnaud Didierlaurent, UNIGE,<br>Switzeland, Veronica Gambillara-<br>Fonck, Pureos Bioventures,<br>Switzerland, Luis Jodar, Pfizer, USA,<br>David Kaslow, FDA, USA, Olga<br>Rovira, Kontivax, Belgium. | + Simone<br>Mérieux<br>+ Nicole<br>Mérieux                      |
| 16:30-17:00  | Break  |   | Restaurant  |
| 17:00-18:30  | Interactive Session 2: Optional lecture from Industry                              | DCVMN and IFPMA members   | Charles<br>Mérieux<br>+   |
|              | ,  |   | Ogobara<br>Doumbo   |
|              | Special lecture: THE 9th LAMBERT   | LECTURE   |   |
| 18:30-18:35  | Introduction   | Paul-Henri Lambert  |   |
| 18:35-19:00  | 16. The future of health   | <b>Andrew Pollard</b> , University of Oxford, UK  | Charles Mérieu  |
| 19:00-19:20  | Discussion   |   |   |
|              |  |   | Restaurant +  |
| 19:20        | Dinner   |   | O. Doumbo   |

# THURSDAY 8 MAY 2025

|             | Inchemi  | O WITT 2020  |  |
|-------------|--|--|--|
| TBC         | Bus from hotels to Les Pensières   |  |  |
| S           | ESSION 3 – VACCINE TECHNOLOGY & A  | MANUFACTURING (PART 2/2)   | Chair: Emily<br>Erbelding,<br>DMID, NIH,<br>USA                        |
| 09:00-09:25 | 17. Delivering a pandemic vaccine in 100 Days:<br>What does it take?   | <b>Jakob Cramer,</b> CEPI, UK  |  |
| 09:25-09:45 | Discussion   |  |  |
| 09:45-10:45 | Interactive session 3 - Q&A  | Panelists:   | Charles<br>Mérieux   |
|             | Everything you always wanted to know on what makes funders support research-development: ask all your questions to governmental agencies, venture capitalists, industry and philanthropic organizations. | Connie Cai, Gates Foundation, USA, Jakob<br>Cramer, CEPI, UK, Emily Erbelding, NIH, USA,<br>Veronica Gambillara, Pureos Bioventures,<br>Switzerland, Luis Jodar, Pfizer, USA.  | Conf room  |
| 10:45-11:00 | Break  |  | Restaurar  |
| S           | SESSION 5 – ASSESSING VACCINES IN C  | LINICAL TRIALS (Part 1/2)  | Chair: Edwi<br>Asturias,<br>Children's<br>Hospital<br>Colorado,<br>USA |
| 11:00-11:25 | 18. Clinical trials: an overview of issues to be considered  | Kathy Neuzil, NIH Fogarty, USA   | 3071   |
| 11:25-11:45 | Discussion   |  | Charles  |
| 11:45-12:10 | 19. Introduction to statistical aspects of clinical trials   | Martha Nason, PATH, USA  | - Mérieux  |
| 12:10-12:30 | Discussion   |  | -  |
| 12:10-12:45 | Working lunch:   | Participants eat at the Restaurant with their group and go back to their room for the SGE 2  | Restaurar  |
| 12:45-15:00 | Small Group Exercise 2:  | 7 Groups:  | Check  |
|             | How to design, recruit volunteers for, and analyze the results of selected phase II trials   | Group 1: S. Aureus: V. Gambillara & B. Gessner<br>Group 2: Ebola: M. Nason & H. Whitaker<br>Group 3: Dengue: N. Baylor & A. Durbin<br>Group 4: RSV: E. Asturias & K. Talaat<br>Group 5: Mpox: K. Johansen<br>Group 6: Typhoid conjugate vaccines: K. Senouci<br>Group 7: Coronavirus: E. Erbelding | Group<br>assignmer<br>and room<br>on board                             |
| 15:00-15:25 | 20. Assessing herd protection and vaccine effectiveness (and use for licensure)  | <b>John Clemens</b> , International Vaccine Institute (IVI), Republic of Korea   |  |
| 15:25-15:45 | Discussion   |  | Charles  |
| 15:45-16:10 | 21. Clinical trials: role of a Data Safety<br>Monitoring Board (DSMB)  | Robert Heyderman, University College<br>London, UK (via Zoom)  | Mérieux  |
| 16:10-16:30 | Discussion   |  | -  |
| 16:30-16:50 | Break  |  | Restaurar  |
| 16:50-17:15 | 22. Human Challenge Trials   | Chris Chiu, Imperial College London, UK  |  |
| 17:15-17:35 | Discussion   |  | Charles<br>Mérieux   |
| 17:35-17:50 | Time for students to reflect personally on the lear  | nings  |  |
| 18:00-19:30 | Dinner   |  | Restaurant +<br>Ooumbo roon  |
|             |  |  |  |

19:30

Bus to Hotels

# **FRIDAY 9 MAY 2025**

| TBC  | Bus from hotels to Les Pensières  |  |   |
|--|---|--|---|
| SE   | ESSION 6 – VACCINE SAFETY - ASSESSMEN   | T OF ADVERSE EFFECTS   | Chair: Kari<br>Johansen, Public<br>Health Agency,<br>Sweden   |
| 09:00-09:25  | 23. How do vaccines cause adverse events? (Including Immune-mediated diseases)  | <b>Kawsar Talaat</b> , Johns Hopkins<br>Bloomberg School of Public Health,<br>USA  | Charles   |
| 09:25-09:45  | Discussion  |  | Mérieux<br>Conf room  |
| 09:45-10:10  | 24. WHO Guidance on how to detect and manage safety issues  | <b>Madhav Balakrishnan</b> , WHO,<br>Switzerland   |   |
| 10:10-10:30  | Discussion  |  | _   |
| 10:30-11:00  | Break   |  | Restaurant  |
| 11:00-11:25  | <b>25. Population-based post-licensure surveillance</b> (including study methodology for signal validation and epi studies)   | Heather Whitaker, UKHSA, UK  | Charles   |
| 11:25-11:45  | Discussion  |  | Mérieux   |
| 11:45-12:10  | 26. Immunization safety in low- and middle-income country vaccination programs  | Kamel Senouci, University of Geneva  | Meneox  |
| 12:10-12:30  | Discussion  |  |   |
|  |   |  |   |
| 12:30-14:00<br>S   | ESSION 5 – ASSESSING VACCINES IN CLIN   | IICAL TRIALS (Part 2/2)  | Restaurant +<br>Ogobara Doumbo  |
| \$<br>14:00-14:30  | ESSION 5 - ASSESSING VACCINES IN CLIN   |  |   |
| S  | ESSION 5 – ASSESSING VACCINES IN CLIN   | 7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbelding   |   |
| \$<br>14:00-14:30  | ESSION 5 — ASSESSING VACCINES IN CLIN  Mentoring  Small group exercise 3:  Vaccine trial Phase III planning, implementation,  | 7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci   | Charles Mérieux O.Doumbo Nicole Mérieux Simone Mérieux Mandallaz Chavoires  |
| \$<br>14:00-14:30<br>14:30-16:40   | ESSION 5 - ASSESSING VACCINES IN CLIN  Mentoring  Small group exercise 3:  Vaccine trial Phase III planning, implementation, analysis of the study results  Time for students to reflect personally on the  | 7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci   | Charles Mérieux O.Doumbo Nicole Mérieux Simone Mérieux Mandallaz Chavoires  |
| \$ 14:00-14:30 14:30-16:40   | ESSION 5 – ASSESSING VACCINES IN CLIN  Mentoring  Small group exercise 3:  Vaccine trial Phase III planning, implementation, analysis of the study results  Time for students to reflect personally on the learnings  | 7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbelding   | Charles Mérieux<br>O.Doumbo<br>Nicole Mérieux<br>Simone Mérieux<br>Mandallaz<br>Chavoires<br>Salon du Dr            |
| \$ 14:00-14:30 14:30-16:40   | ESSION 5 – ASSESSING VACCINES IN CLIN  Mentoring  Small group exercise 3:  Vaccine trial Phase III planning, implementation, analysis of the study results  Time for students to reflect personally on the learnings  Break   | 7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbelding   | Charles Mérieux<br>O.Doumbo<br>Nicole Mérieux<br>Simone Mérieux<br>Mandallaz<br>Chavoires<br>Salon du Dr            |
| \$ 14:00-14:30 14:30-16:40  16:40-14:55 16:55-17:10                                      | ESSION 5 – ASSESSING VACCINES IN CLIN  Mentoring  Small group exercise 3:  Vaccine trial Phase III planning, implementation, analysis of the study results  Time for students to reflect personally on the learnings  Break  Special lecture: THE 17 <sup>TI</sup>  | 7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbelding   | Charles Mérieux<br>O.Doumbo<br>Nicole Mérieux<br>Simone Mérieux<br>Mandallaz<br>Chavoires<br>Salon du Dr            |
| \$ 14:00-14:30 14:30-16:40  16:40-14:55 16:55-17:10                                      | ESSION 5 – ASSESSING VACCINES IN CLIN  Mentoring  Small group exercise 3:  Vaccine trial Phase III planning, implementation, analysis of the study results  Time for students to reflect personally on the learnings  Break  Special lecture: THE 17 <sup>TI</sup> Introduction  27. Multiple Antigen Presenting System Vaccines                    | 7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbelding  H PLOTKIN LECTURE  Edwin Asturias, Children's Hospital Colorado, USA  Rick Malley, Boston Children's | Charles Mérieux O.Doumbo Nicole Mérieux Simone Mérieux Mandallaz Chavoires Salon du Dr  Restaurant  Charles         |
| \$ 14:00-14:30 14:30-16:40  16:40-14:55 16:55-17:10  17:10-17:15 17:15-17:40             | ESSION 5 – ASSESSING VACCINES IN CLIN  Mentoring  Small group exercise 3:  Vaccine trial Phase III planning, implementation, analysis of the study results  Time for students to reflect personally on the learnings  Break  Special lecture: THE 17 <sup>TI</sup> Introduction  27. Multiple Antigen Presenting System Vaccines (MAPS)             | 7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbelding  H PLOTKIN LECTURE  Edwin Asturias, Children's Hospital Colorado, USA  Rick Malley, Boston Children's | Charles Mérieux O.Doumbo Nicole Mérieux Simone Mérieux Mandallaz Chavoires Salon du Dr  Restaurant  Charles         |
| \$ 14:00-14:30 14:30-16:40  16:40-14:55 16:55-17:10  17:10-17:15 17:15-17:40 17:40-18:00 | ESSION 5 — ASSESSING VACCINES IN CLIN  Mentoring  Small group exercise 3:  Vaccine trial Phase III planning, implementation, analysis of the study results  Time for students to reflect personally on the learnings  Break  Special lecture: THE 17 <sup>TI</sup> Introduction  27. Multiple Antigen Presenting System Vaccines (MAPS)  Discussion | 7 Groups: Group 1: V. Gambillara & B. Gessner Group 2: M. Nason & H. Whitaker Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbelding  H PLOTKIN LECTURE  Edwin Asturias, Children's Hospital Colorado, USA  Rick Malley, Boston Children's | Charles Mérieux O.Doumbo Nicole Mérieux Simone Mérieux Mandallaz Chavoires Salon du Dr  Restaurant  Charles Mérieux |

#### SATURDAY 10 MAY 2025

**TBC** Bus from hotels to Les Pensières

|             | SESSION 7 - ETHICAL ISS   | SUES   | <u>Chair:</u> Kari<br>Johansen,<br>Public Health<br>Agency,<br>Sweden      |
|-------------|---|--|--|
| 09:00-09:25 | 28. Applied ethics in immunization programs and practice  | <b>Anuradha Rose</b> , Christian Medical<br>College of Vellore, India  |  |
| 09:25-09:45 | Discussion  |  | Charles<br>Mérieux   |
| 09:45-10:10 | 29. Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines | Catherine Slack, University of KwaZulu-<br>Natal, South Africa   | conf room  |
| 10:10-10:30 | Discussion  |  | _  |
| 10:30-10:50 | Break   |  | Restaurant   |
| 10:50-13:00 | Small group exercise 4:  Ethical considerations in vaccine trials                                   | Facilitators (7 Groups):  Edwin Asturias, Kari Johansen, Anuradha Rose, Kamel Senouci, Catherine Slack, Martha Nason, Kawsar Talaat. | Charles Mérieux O.Doumbo Nicole Mérieux Simone Mérieux Mandallaz Chavoires |
| 13:00-13:10 | Time for students to reflect personally on the learnings of the morning                             |  | Salon du Dr  |
| 13:10-13:40 | Picnic  |  | Take away or<br>eat at the<br>Restaurant                                   |
| 13:40       | Bus to Hotels and Free time in the afternoon  |  |  |
| TBC         | Bus from Hotels to Les Pensières  |  | _  |
| TBC         | Dinner upon Registration  |  | Restaurant   |
| TBC         | Bus from Les Pensières to Hotels  |  |  |

|     | SUNDAY 11 MAY 2025                                 |            |
|-----|--|------------|
| TBC | Bus from hotels to Les Pensières (for dinner only) |            |
| TBC | Dinner upon registration                           | Restaurant |
| TBC | Bus from Les Pensières to Hotel                    |            |

|                           | MONDAY 12   | MAY 2025   |   |
|---------------------------|---|--|---|
| TBC                       | Bus from hotels to Les Pensières  |  |   |
| 09:00-09:10               | Ethical considerations in vaccine trials: Recap   | Catherine Slack, University of KwaZulu-Natal, South Africa   | Charles<br>Mérieux conf.<br>Room  |
|                           | SESSION 8 – DECISION MAKING FOR   | VACCINES (Part 1/2)  | <u>Chair:</u> Kamel<br>Senouci,<br>UNIGE  |
| 09:10-09:35               | <b>30. The decision-making processes for vaccines u</b> global, regional and local perspectives   | use: Rudzani Muloiwa, University of Cape<br>Town, South Africa   |   |
| 09:35-09:55               | Discussion  |  | Charles   |
| 09:55-10:20               | 31. The decision-making processes for vaccines' use: what should experts consider   | <b>Kari Johansen</b> , Public Health Agency of Sweden  | – Mérieux   |
| 10:20-10:40               | Discussion  |  | _   |
| 10:40-11:10               | Break   |  | Restaurant  |
| 11:10-11:35               | 32. The example of the WHO SAGE decision making processes   | <b>Joachim Hombach</b> , WHO Geneva,<br>Switzerland  |   |
| 11:35-11:55               | Discussion  |  | Charles   |
| 11:55-12:20               | 33. The role of health economics (including modelling) as a tool in analyzing vaccine policy options  | <b>Marc Brisson</b> , Université de Laval,<br>Canada   | Mérieux   |
| 12:20-12:40               | Discussion  |  | _   |
| 12:40-13:40               | Lunch   |  | Restaurant  |
| 13:40-15:50               | and impact assessment of new vaccines introduced in selected countries: safety and effectiveness.  Gro  | pup 1: Rotavirus: K. Talaat pup 2: HPV: K. Senouci pup 3: Dengue LMICs: B. Gessner & H. Nohynek pup 4: Zoster: K. Johansen pup 5: Malaria: K. Neuzil pup 6: RSV Adults: K. Talbot pup 7: RSV: J. Englund | Charles Mérieux + O. Doumbo +Simone Mérieux + Nicole Mérieux+ Chavoires + Mandallaz + Salon du Dr |
| 15:50-16:20               | Break   |  | Restaurant  |
|                           | SESSION 9 - UPDATES ON VAC  | CINES (part 1/4)   | Chair: Anna<br>Durbin, Johns<br>Hopkins School<br>of Public<br>Health, USA                        |
| 16:20-16:45               | 34. Polysaccharide and conjugate vaccines   | <b>David Goldblatt</b> , University College London, UK   |   |
| 16:45-17:05               | Discussion  |  | Charles   |
| 17:05-17:30               | <b>35. Pneumococcal conjugate vaccines:</b> the imposof PCV, its introduction in different populations (including adults & children) and the change in Pvalency stereotypes | USA  | – Mérieux conf.<br>Room   |
| 17:30-17:50               | Discussion  |  | _   |
| 17:50-18:35               | Mentoring   |  | Check<br>boards for   |
| 18:35-18:50               | Time for students to reflect personally on the learnings  |  | group<br>assignments  |
| 18:50- <mark>20:00</mark> | Dinner  |  | Restaurant +<br>O. Doumbo   |
| 20:00                     | Bus to Hotels   |  |   |

#### **TUESDAY 13 MAY 2025**

| TBC          | Bus from hotels to Les Pensières  |  |  |
|--------------|---|--|--|
|              | SESSION 9 – UPDATES ON VACCIN   | NES (part 2/4)   | Chair: Anna<br>Durbin, John<br>Hopkins<br>School of<br>Public<br>Health, USA |
| 09:00-09:25  | 36. HPV vaccines  | Margaret Stanley, Cambridge University, UK (via Zoom)                    | Charles  |
| 09:25-09:45  | Discussion  |  | Mérieux<br>conf. Room  |
| 09:45-10:10  | 37. Typhoid vaccines  | Kathy Neuzil, NIH Fogarty, USA   | _ COIII. ROOII   |
| 10:10-10:30  | Discussion  |  | _  |
| 10:30-11:00  | Break   |  | Restaurant   |
| 11:00-11:25  | 38. Meningococcal vaccines  | Shamez Ladhani, UKHSA, UK  |  |
| 11:25-11:45  | Discussion  |  | _  |
| 11:45-12:10  | 39. Vaccines against arboviruses (Dengue, Zika,<br>Chikungunya)                         | Anna Durbin, Johns Hopkins<br>Bloomberg School of Public Health,<br>USA  | Charles<br>Mérieux   |
| 12:10-12:30  | Discussion  |  | _  |
| 12:30-12:40  | Time for students to reflect personally on the learning                                 | S  | _  |
| 12:40-14:10  | Lunch   |  | Restaurant<br>O. Doumb   |
| 14:10-14:35  | 40. Rotavirus and norovirus vaccines  | Umesh Parashar, Centers for Disease<br>Control, Atlanta, USA             |  |
| 14:35-14:55  | Discussion  |  | _  |
| 14:55-15:20  | 41. Flu vaccines  | <b>Kanta Subbarao</b> , Université de Laval,<br>Canada                   | Charles<br>Mérieux   |
| 15:20-15:40  | Discussion  |  |  |
| 15:40-16:05  | 42. COVID vaccines  | <b>Hanna Nohynek</b> , Finnish Institute for Health and Welfare, Finland |  |
| 16:05- 16:25 | Discussion  |  |  |
| 16:25-16:55  | Break   |  | Restaurant   |
|              | SESSION 8 - DECISION MAKING FO  | OR VACCINES (Part 2/2)   |  |
| 16:55-18:05  | Small group exercise 6  | Restitution of the 7 Groups from   |  |
|              | Sharing recommendations with the Authorities on the impact on the immunization program. | Exercise 5   | Charles<br>Mérieux<br>room   |
| 18:05-18:20  | Time for students to reflect personally on the learnings                                |  |  |
| 18:30-20:00  | Dinner  |  | Restaurant<br>Ogobara<br>Doumbo<br>room                                      |
| 20:00        | Bus to Hotels   |  |  |

#### WEDNESDAY 14 MAY 2025

| SESSION 10 - SELECTING APPROPRIATE VACCINATION STRATEGIES  99:00-09:25  43. 85V  | TBC         | Bus from Hotels to les Pensières                   |  |   |
|--|-------------|--|--|---|
| National decision-making for immunization programmes   National decision-making for immunization program performance   National decision-making for immunization program performance   National decision-making for immunization program performance   National decision-making for immunization programmes   National decision-making for immunization programmes   National decision-making for immunization programmes   National decision-making for immunization   National decision-making for immuniza   |             | SESSION 10 - SELECTING APPROPRIATE VAC             | CINATION STRATEGIES  | Chair: Hanno<br>Nohynek,<br>Finnish<br>Institute for<br>Health and<br>Welfare,<br>Finland |
| 09:25-09:45 Discussion  44. Vaccination and pregnancy and early life Christiane Eberhardt, University of Geneva, Switzerland (via Zoom)  10:10-10:30 Discussion  10:30-11:00 Brook Rest  11:00-11:25 ds. Vaccination schedules: Past, present and future - is there some rationale?  11:45-12:10 de. Vaccine responses and efficacy in the elderly WSA  12:10-12:30 Discussion  12:30-12:55 d7. Vaccination in immuno-compromised individuals  12:55-13:15 Discussion  14:45-14:51 Lunch Rest  14:45-16:25 PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1. National decision-making for immunization programmes  1. Notional decision-making for immunization programmes  1. New approaches towards vaccination e-registries Parameter WHO Geneva, and Karl Johansen, Public Health Agency, and Karl Johansen, Public Health Agency and Agency and Karl Johansen, Public Health Agency and Karl Johansen, Public Health Agency and Agency and Agency a | 09:00-09:25 | 43. RSV  | Washington/Seattle Children's  | Charles   |
| 09:45-10:10 44. Vaccination and pregnancy and early life Geneva, Switzerland (via Zoom)  10:10-10:30 Discussion  10:30-11:00 Break Resta  11:00-11:25 45. Vaccination schedules: Past, present and future - is there some rationale? Colorado, USA  11:25-11:45 Discussion  11:45-12:10 46. Vaccine responses and efficacy in the elderly USA  Discussion  12:30-12:55 47. Vaccination in immuno-compromised individuals Discussion  13:15-14:45 Lunch Resta  14:45-16:25 PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1   | 09:25-09:45 | Discussion   |  | Mérieux   |
| 10:30-11:00 Break Edwin Asturias, Children's Hospital Colorado, USA 11:20-11:25 45. Vaccination schedules: Past, present and future - is there some rationale? Edwin Asturias, Children's Hospital Colorado, USA 11:25-11:45 Discussion 11:45-12:10 46. Vaccine responses and efficacy in the elderly USA 12:10-12:30 Discussion 12:30-12:55 47. Vaccination in immuno-compromised individuals IBC 12:55-13:15 Discussion 13:15-14:45 Lunch Res 14:45-16:25 PARALLEL SESSIONS (rotation of two 45 min-Sessions) 15:45-16:45 PARALLEL SESSIONS (rotation of two 45 min-Sessions) 16:26-16:45 PARALLEL SESSIONS (rotation of two 45 min-Sessions) 16:27-16:45 PARALLEL SESSIONS (rotation of two 45 min-Sessions) 16:28-16:45 PA | 09:45-10:10 | 44. Vaccination and pregnancy and early life       |  | – conf. Room  |
| 11:00-11:25 45. Vaccination schedules: Past, present and future - is there some rationale?  11:25-11:45 Discussion  11:45-12:10 46. Vaccine responses and efficacy in the elderly USA  12:10-12:30 Discussion  12:30-12:55 47. Vaccination in immuno-compromised individuals 18C  12:55-13:15 Discussion  13:15-14:45 Lunch  PARALLEL SESSIONS (rotation of two 45 min-Sessions)  14:45-16:25 PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1. National decision-making for immunization programmes  Aleisandro Diana, University of Geneva & Melinda Wharton, US-CDC, Louise Henotf, WHO  2. Clinical vaccinology: patients' problem solving  3. New approaches towards vaccination e-registries  4. Cold Chain management Souleymane Kone, WHO Geneva, and Kari Johansen. Public Health Agency, Sweden  5. Monitoring immunization program performance Jan Grevendonk & Laure Dumolard, MHO Geneva  6. AEFI causality assessment Madhav Balakrishnan, WHO, Geneva  16:25-16:45 Break  SESSION 9 - UPDATES ON VACCINES (Part 3/4)  16:45-17:10 48. Cholera vaccines  Alejandro Cravieto, National Autonomous University of Mexico  Chair Asti Causality of Mexico  Chair Asti Causality of Mexico  Discussion  Alejandro Cravieto, National Autonomous University of Mexico  Chair Asti Causality of Mexico  Discussion  Discussion  Discussion  Alejandro Cravieto, National Autonomous University of Mexico  Chair Asti Causality of Mexico  Chair Asti Causality of Mexico  Discussion  Dis | 10:10-10:30 | Discussion   |  | _   |
| and future - is there some rationale? Colorado, USA  11:25-11:45 Discussion 11:45-12:10 46. Vaccine responses and efficacy in the elderly USA  12:10-12:30 Discussion 12:30-12:55 47. Vaccination in immuno-compromised individuals IBC  12:55-13:15 Discussion 13:15-14:45 Lunch  PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1. National decision-making for immunization programmes  1. National decision-making for immunization programmes  2. Clinical vaccinology: patients' problem solving 3. New approaches towards vaccination e-registries Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden  5. Monitoring immunization program performance Jan Grevendonk & Laure Dumolard, WHO Geneva 6. AEFI causality assessment Madhav Balakrishnan, WHO, Geneva 6. AEFI causality assessment Madhav Balakrishnan, WHO, Geneva 16:25-16:45 Breck  SESSION 9 - UPDATES ON VACCINES (Part 3/4)  16:45-17:10 48. Cholera vaccines  Alejandro Cravioto, National Autonomous University of Mexico Mexicology. Mexic | 10:30-11:00 | Break  |  | Restaurant  |
| 11:45-12:10 46. Vaccine responses and efficacy in the elderly USA  12:10-12:30 Discussion  12:30-12:55 47. Vaccination in immuno-compromised individuals BC  12:55-13:15 Discussion  13:15-14:45 Lunch Res  PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1. National decision-making for immunization programmes  2. Clinical vaccinology: patients' problem solving Alessandro Diana, University of Geneva Melinda Wharton, US-CDC, Louise Henaff, WHO  3. New approaches towards vaccination e-registries Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden  4. Cold Chain management Souleymane Kone, WHO Geneva Man 5. Monitoring immunization program performance Jan Grevendonk & Laure Dumolard, MHO Geneva  6. AEFI causality assessment Madhav Balakrishnan, WHO, Geneva Restance Sessions  SESSION 9 - UPDATES ON VACCINES (Part 3/4)  16:45-17:10 48. Cholera vaccines Alejandro Cravioto, National Autonomous University of Mexico  Chair Meissance Conf.  Alejandro Cravioto, National Autonomous University of Mexico  Chair Meissance Conf.  Alejandro Cravioto, Discussion  17:10-17:30 Discussion  Esstance Conf.  Restance Conf.  Bisao-20:00 Dinner upon registration  | 11:00-11:25 | · ·  |  |   |
| 12:10-12:30 Discussion 12:30-12:55 47. Vaccination in immuno-compromised individuals IBC 12:55-13:15 Discussion 13:15-14:45 Lunch  PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1. National decision-making for immunization programmes  Programmes  2. Clinical vaccinology: patients' problem solving 3. New approaches towards vaccination e-registries  4. Cold Chain management 5. Monitoring immunization program performance 4. Cold Chain management 5. Monitoring immunization program performance 4. AEFI causality assessment  Madhav Balakrishnan, WHO, Geneva  16:25-16:45 Break  SESSION 9 - UPDATES ON VACCINES (Part 3/4)  16:45-17:10 48. Cholera vaccines  Alejandro Cravioto, National Autonomous University of Mexico  Chair Mé Mé Mé Mé Messardro Diana, University of Mexico Mé  | 11:25-11:45 | Discussion   |  | _   |
| 12:30-12:55 47. Vaccination in immuno-compromised individuals IBC  12:55-13:15 Discussion  13:15-14:45 Lunch  PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1. National decision-making for immunization programmes  1. National decision-making for immunization programmes  2. Clinical vaccinology: patients' problem solving Alessandro Diana, University of Geneva 3. New approaches towards vaccination e-registries Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden  4. Cold Chain management Souleymane Kone, WHO Geneva Man 5. Monitoring immunization program performance Jan Grevendonk & Laure Dumolard, Mike Geneva  6. AEFI causality assessment Madhav Balakrishnan, WHO, Geneva O. Do Destantion of the decision of two 45 min-Sessions)  16:25-16:45 Break  SESSION 9 - UPDATES ON VACCINES (Part 3/4)  16:45-17:10  18:30-20:00 Dinner upon registration  Restantia  | 11:45-12:10 | 46. Vaccine responses and efficacy in the elderly  |  | Charles<br>Mérieux  |
| 12:55-13:15 Discussion  13:15-14:45 Lunch  Res  14:45-16:25 PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1. National decision-making for immunization programmes  1. National decision-making for immunization programmes  2. Clinical vaccinology: patients' problem solving  3. New approaches towards vaccination e-registries  3. New approaches towards vaccination e-registries  4. Cold Chain management Souleymane Kone, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden  5. Monitoring immunization program performance Jan Grevendonk & Laure Dumolard, Me MO Geneva  6. AEFI causality assessment Madhav Balakrishnan, WHO, Geneva O. Do. Do. Do. Do. Do. Do. Do. Do. Do. Do  | 12:10-12:30 | Discussion   |  | _   |
| 13:15-14:45 Lunch  PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1. National decision-making for immunization programmes  1. National decision-making for immunization programmes  2. Clinical vaccinology: patients' problem solving Alessandro Diana, University of Geneva 3. New approaches towards vaccination e-registries Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden  4. Cold Chain management Souleymane Kone, WHO Geneva Man 5. Monitoring immunization program performance Jan Grevendonk & Laure Dumolard, Nic WHO Geneva  6. AEFI causality assessment Madhav Balakrishnan, WHO, Geneva O. Do. 16:25-16:45 Break Restormance Session Alejandro Cravioto, National Autonomous University of Mexico  16:45-17:10  48. Cholera vaccines Alejandro Cravioto, National Autonomous University of Mexico  Chair Mexicology of Mexico  Chair Astronomous University of Mexico  Chair Autonomous University of Mexico  Chair Mexicology of Mexico  Chair Autonomous University of Mexico  Chair Mexicology of Mexicology of Mexico  Chair Mexicology of Mexicology of Mexico  Chair Mexicology of Mexicology of Mexicology of Mexicology of Mexicolog | 12:30-12:55 | 47. Vaccination in immuno-compromised individuals  | TBC  | _   |
| 14:45-16:25  PARALLEL SESSIONS (rotation of two 45 min-Sessions)  1. National decision-making for immunization programmes  1. National decision-making for immunization programmes  1. National decision-making for immunization programmes  2. Clinical vaccinology: patients' problem solving Alessandro Diana, University of Geneva  3. New approaches towards vaccination e-registries Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden  4. Cold Chain management Souleymane Kone, WHO Geneva Man 5. Monitoring immunization program performance Jan Grevendonk & Laure Dumolard, Mé WHO Geneva  6. AEFI causality assessment Madhav Balakrishnan, WHO, Geneva O. Dot Reste Child Asta Session Session Alejandro Cravioto, National Autonomous University of Mexico  16:45-17:10  48. Cholera vaccines Alejandro Cravioto, National Autonomous University of Mexico  17:10-17:30 Discussion Reste  | 12:55-13:15 | Discussion   |  | _   |
| 1. National decision-making for immunization programmes  1. National decision-making for immunization programmes  2. Clinical vaccinology: patients' problem solving Alessandro Diana, University of Geneva  3. New approaches towards vaccination e-registries Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden  4. Cold Chain management Souleymane Kone, WHO Geneva Man Souleymane Kone, WHO Geneva Man Souleymane Kone, WHO Geneva Man Mahor Geneva  6. AEFI causality assessment Madhav Balakrishnan, WHO, Geneva O. Dother Meisser Child Hospital Series (Part 3/4)  16:25-16:45 Break  SESSION 9 – UPDATES ON VACCINES (Part 3/4)  16:45-17:10 48. Cholera vaccines Alejandro Cravioto, National Autonomous University of Mexico  17:10-17:30 Discussion  Discussion Resta  | 13:15-14:45 | Lunch  |  | Restaurar   |
| Programmes   Melinda Wharton, US-CDC, Louise   Mélenaff, WHO   | 14:45-16:25 | PARALLEL SESSIONS (rotati                          | on of two 45 min-Sessions)   |   |
| Session   Sess   |             |  | Melinda Wharton, US-CDC, Louise  | Charles<br>Mérieux  |
| Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden  4. Cold Chain management 5. Monitoring immunization program performance Meanumer Agency, Sweden  5. Monitoring immunization program performance Meanumer Agency, Sweden  5. Monitoring immunization program performance Men Geneva Men Medhav Balakrishnan, WHO, Geneva Men Men Madhav Balakrishnan, WHO, Geneva  Chair Asta Chilc As |             |  | Geneva   | Salon du Di   |
| 5. Monitoring immunization program performance  6. AEFI causality assessment  8. AEFI causality assessment  8. AEFI causality assessment  8. AEFI causality assessment  8. Break  8. Chair Astr. Child Hos Color U  16:45-17:10  16:45-17:10  18:30-20:00  19 Dinner upon registration   |             | 3. New approaches towards vaccination e-registries | <b>Danovaro</b> , WHO Geneva, and <b>Kari</b><br><b>Johansen</b> , Public Health Agency, | Simone<br>Mérieux   |
| WHO Geneva  6. AEFI causality assessment  Madhav Balakrishnan, WHO, Geneva  Resta  SESSION 9 - UPDATES ON VACCINES (Part 3/4)  16:45-17:10  48. Cholera vaccines  Alejandro Cravioto, National Autonomous University of Mexico  Mé  Conf.  Asserta  Chair Astro Chike Chike Hos Color U  17:10-17:30  Discussion  Discussion  Resta  |             |  | -  | Mandallaz   |
| 16:25-16:45       Break       Resta         SESSION 9 - UPDATES ON VACCINES (Part 3/4)       Chair Asta Chille Hos Cold UT         16:45-17:10       48. Cholera vaccines       Alejandro Cravioto, National Autonomous University of Mexico       Ch. Mé         17:10-17:30       Discussion       conf.         18:30-20:00       Dinner upon registration       Resta  |             | 5. Monitoring immunization program performance     | •  | Nicole<br>Mérieux   |
| SESSION 9 - UPDATES ON VACCINES (Part 3/4)  16:45-17:10  | 16:25-16:45 |  | Madhav Balakrishnan, WHO, Geneva   | O. Doumbo   |
| Autonomous University of Mexico  17:10-17:30 Discussion  18:30-20:00 Dinner upon registration  Autonomous University of Mexico  Ch  Mé  conf.  |             | SESSION 9 – UPDATES ON VACCIN                      | ES (Part 3/4)  | Chair: Edwii<br>Asturias,<br>Children's<br>Hospital<br>Colorado,<br>USA                   |
| 18:30-20:00 Dinner upon registration Resta   |             |  |  | Charles<br>Mérieux  |
| ,  |             |  |  | conf. Room  |
| 20:00 Bus to Hotels  |             | Dinner upon registration                           |  | Restaurant  |
|  | 20:00       | Bus to Hotels                                      |  |   |

#### THURSDAY 15 MAY 2025

| TBC                | Bus from hotels to Les Pensières   |  |   |
|--------------------|--|--|---|
|                    | SESSION 9 – UPDATES ON VACCIN  | ES (Part 4/4)  | Chair: Edwir<br>Asturias,<br>Children's<br>Hospital<br>Colorado,<br>USA |
| 09:00-09:25        | 49. Non-specific effects of vaccines   | <b>Nigel Curtis</b> , The Royal Children's<br>Hospital, Melbourne, Australia   | Charles   |
| 09:25-09:45        | Discussion   |  | Mérieux   |
| 09:45-10:10        | 50. Malaria vaccines   | Mary Hamel, WHO, Geneva  | _ conf. Room  |
| 10:10-10:30        | Discussion   |  | _   |
| 10:30-11:00        | Break  |  | Restaurant  |
| 11:00-11:25        | 51. Tuberculosis vaccines  | <b>Helen McShane</b> , University of Oxford, UK  | Charles<br>Mérieux  |
| 11:25-11:45        | Discussion   |  |   |
|                    | SESSION 11 – REACHING SPECIFI  | C GROUPS   | Chair: Kame<br>Senouci,<br>University of<br>Geneva                      |
| 11:45-12:10        | 52. How to better reach the zero-dose or under-<br>vaccinated children in LMICs                  | Narendra Arora, INCLEN, India  |   |
| 12:10-12:30        | Discussion   |  | –<br>Charles  |
| 12:30-12:55        | 53. Life-course vaccines: how to better reach individuals from childhood to elderly?             | <b>Pierre Vandamme</b> , University of Antwerp, Belgium  | – Mérieux   |
| 12:55-13:15        | Discussion   |  | _   |
| 13:15-14:15        | Lunch  | Ogobar   | Restaurant<br>a Doumbo roo  |
| 14:15-14:40        | 54. The determinants of vaccine acceptance   | <b>Eve Dubé</b> , Université de Laval,<br>Canada   | <u>a Boombo 100</u>   |
| 14:40-15:00        | Discussion   |  | _   |
| 15:00-16:00        | Interactive session 4  How to address vaccine hesitancy at individual and community levels?  Q&A | Steve Lewandowsky, Bristol University Eve Dubé, Université de Laval Naveen Thacker, International Pediatric Association Alejandro Cravioto, National Autonomous University of Mexico | Charles<br>Mérieux  |
| 16:00-16:20        | Break  | <u> </u>   | Restaurant  |
|                    | Special Session: 25 YEARS OF   | ADVAC  | <u>Chair:</u><br><mark>TBC</mark>                                       |
| 16:20-18:00        | 25 years of ADVAC, what impact and what future? Panel (Panelists and Alumni)                     | Panelists: Stanley Plotkin, Paul-Henri<br>Lambert, Alain Merieux<br>Alumni: Benjamin Kagina (University<br>of Cape Town, South Africa) & Helen<br>Matzger (Gates Foundation, USA)    | Charles<br>Mérieux  |
| 18:00              | Bus departure from les Pensières to hotels (check boar   | d for return bus from hotels to the Mentho   | n Castle)   |
| 19:00              | Bus departure from Les Pensières to Château de Menth   | on Saint   | Meet at the<br>Reception  |
|                    | Bernard for visit of the castle and the ADVAC 25 Gala  | Dinner   | Lobby   |
| 22:30 and<br>00:00 | Buses from Château de Menthon to les Pensières & Ho  | tels   |   |

#### **FRIDAY 16 MAY 2025**

| TBC         | Bus from hotels to Les Pensières  |   |  |
|-------------|---|---|--|
| SESSION     | 2: FACING THE MEDIA: WHAT THE VACCINOL CONTEXT OF VACCINE HESITANCY AND                                       |   | <u>Chair:</u> Kamel<br>Senouci,<br>UNIGE |
| 09:00-11:00 |   | <b>Deborah Hall</b> , Broadcaster and Media                                   | Dr. Charles                              |
|             | Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups | Affairs Consultant, London, UK  | Mérieux conf.<br>Room                    |
| 11:00-11:20 | Break   |   | Restaurant                               |
| 11:20-13:20 | ,   | <b>Deborah Hall</b> , Broadcaster and Media<br>Affairs Consultant, London, UK | Charles<br>Mérieux                       |
| 13:20-14:20 | Lunch   |   | Restaurant +<br>O. Doumbo                |
|             | SESSION 13: CLOS  | ING   |  |
| 14:20-14:50 | Time for participants to complete the final evaluation  |   | Charles                                  |
| 14:50-15:30 | •   | <b>Kamel Senouci</b> , Director, ADVAC,<br>University of Geneva               | Mérieux                                  |
| TBC         | Bus from Les Pensières to hotels (check boards for Schedule)  |   |  |

#### **OPTIONAL LECTURE**

| WEDNESDAY 7 MAY 2025                                      |   |  |   |
|---|---|--|---|
| SESSION 3: VACCINE TECHNOLOGY, MANUFACTURING AND APPROVAL |   |  | Chair: Kamel<br>Senouci,<br>Director<br>ADVAC,<br>University of<br>Geneva |
| 17:00-18:30   | Interactive Session 2   | Luis Jodar, Pfizer, USA & Rajinder Suri, DCVMN | Room  |
|   | <b>From ideas to implementation -</b> the realities of funding for vaccine research and development in the private sector |  | Charles<br>Mérieux  |
|   |   |  | (Luis Jodar)<br>+   |
|   |   |  | Room Nicole   |
|   | Two 45-minutes sessions (2 groups switching) Group A: starting with Rajinder Suri Group B: starting with Luis Jodar       |  | Mérieux<br>(Rajinder  |
|   |   |  | Suri)   |

